1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Moberg Pharma AB (publ)

Moberg Pharma AB (publ)

MOB.ST
Moberg Pharma AB (publ)SE flagStockholm Stock Exchange
9.39
SEK
-0.06
- -
441.34MMarket Cap

Total Valuation

Moberg Pharma AB (publ) carries a market capitalization of 441.34M, placing it among publicly traded companies globally. Its enterprise value stands at 263.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap441.34M
Enterprise Value263.11M

Share Statistics

Moberg Pharma AB (publ) currently has 47.00M shares outstanding.

Shares Outstanding47.00M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 33.13, and the price-to-book ratio stands at -0.84.

PE RatioN/A
PS Ratio33.13
PB Ratio-0.84
P/TBV Ratio1.55
P/FCF Ratio-384.65
P/OCF Ratio-39.53

Enterprise Valuation

EV / Sales18.03
EV / EBITDAN/A
EV / EBITN/A
EV / FCF27.86

Financial Position

Moberg Pharma AB (publ) maintains a current ratio of 13.12, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.32, indicating conservative leverage, while an interest coverage ratio of -158.51 demonstrates limited ability to service its debt obligations.

Current Ratio13.12
Quick Ratio12.43
Debt / Equity0.32
Debt / EBITDA-0.09
Interest Coverage-158.51

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-3.71
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.06

Taxes

Income Tax3.67M
Effective Tax RateN/A

Stock Price Statistics

Moberg Pharma AB (publ)'s stock has gained approximately 5.98194% over the past 52 weeks. The 50-day moving average sits at 10.35, while the 200-day moving average is 9.71.

Beta (5Y)N/A
52-Week Price Change5.98194%
50-Day Moving Average10.35
200-Day Moving Average9.71
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Moberg Pharma AB (publ) generated 14.59M in revenue and converted that into -25.73M in net income, yielding earnings per share of -0.53. EBITDA reached -25.04M, while operating income came in at -25.04M.

Revenue14.59M
Gross Profit8.37M
Operating Income-25.04M
Pretax Income-22.06M
Net Income-25.73M
EBITDA-25.04M
EBIT-25.04M
Earnings Per Share (EPS)-0.53

Balance Sheet

Moberg Pharma AB (publ) holds 222.50M in cash and equivalents against 2.14M in total debt, resulting in a net debt position of -222.50M. Total book value stands at -575.14M, with working capital of 217.08M providing operational flexibility.

Cash & Cash Equivalents222.50M
Total Debt2.14M
Net Debt-222.50M
Equity (Book Value)-575.14M
Book Value Per Share-12.28
Working Capital217.08M

Cash Flow

Moberg Pharma AB (publ) produced -12.23M in operating cash flow over the past twelve months. After subtracting -10.94M in capital expenditures, free cash flow totaled -23.17M - equivalent to -0.49 per share.

Operating Cash Flow-12.23M
Capital Expenditures-10.94M
Free Cash Flow-23.17M
FCF Per Share-0.49

Margins

Moberg Pharma AB (publ) operates with a gross margin of 57.38, reflecting its pricing power and cost economics. The operating margin of -171.63 and net profit margin of -176.32 provide insight into operational efficiency.

Gross Margin57.38
Operating Margin-171.63
Pretax Margin-151.18
Profit Margin-176.32
EBITDA Margin-171.63

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.35
FCF Yield-0.26

Stock Splits

Moberg Pharma AB (publ)'s most recent stock split took place on August 11, 2023 with a 2:3 split ratio.

Last Split Date8/11/2023
Split Ratio2:3

Scores

Moberg Pharma AB (publ) posts an Altman Z-Score of 13.76, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score13.76